Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.4944
+0.1100 (28.62%)
At close: Jan 9, 2026, 4:00 PM EST
0.4991
+0.0047 (0.95%)
After-hours: Jan 9, 2026, 7:59 PM EST
Mereo BioPharma Group Stock Forecast
MREO's stock price has decreased by -86.85% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts that cover Mereo BioPharma Group stock have a consensus rating of "Buy" and an average price target of $4.30, which forecasts a 769.74% increase in the stock price over the next year. The lowest target is $0.50 and the highest is $8.00.
Price Target: $4.30 (+769.74%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Mereo BioPharma Group stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $7 → $0.5 | Strong Buy → Hold | Downgrades | $7 → $0.5 | +1.13% | Dec 30, 2025 |
| BTIG | BTIG | Strong Buy Maintains $6 → $1 | Strong Buy | Maintains | $6 → $1 | +102.27% | Dec 29, 2025 |
| LifeSci Capital | LifeSci Capital | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 29, 2025 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +911.33% | Dec 22, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +1,113.59% | Dec 18, 2025 |
Financial Forecast
Revenue This Year
17.20M
Revenue Next Year
45.38M
from 17.20M
Increased by 163.84%
EPS This Year
-0.06
from -0.29
EPS Next Year
-0.05
from -0.06
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 37.6M | 79.4M | ||||
| Avg | 17.2M | 45.4M | ||||
| Low | 490,000 | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 361.5% | ||||
| Avg | - | 163.8% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.06 | -0.03 | ||||
| Avg | -0.06 | -0.05 | ||||
| Low | -0.06 | -0.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.